Bank of New York Mellon Corp Purchases 14,041 Shares of Natera, Inc. $NTRA

Bank of New York Mellon Corp increased its position in Natera, Inc. (NASDAQ:NTRA) by 2.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 652,931 shares of the medical research company’s stock after buying an additional 14,041 shares during the period. Bank of New York Mellon Corp’s holdings in Natera were worth $149,580,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of NTRA. Horizon Investments LLC acquired a new stake in Natera in the 3rd quarter worth $32,000. Flagship Harbor Advisors LLC acquired a new stake in Natera in the 4th quarter worth $41,000. Sound Income Strategies LLC grew its position in Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after purchasing an additional 45 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new stake in Natera in the 4th quarter worth $62,000. Finally, Fifth Third Bancorp grew its position in Natera by 123.4% in the 4th quarter. Fifth Third Bancorp now owns 324 shares of the medical research company’s stock worth $74,000 after purchasing an additional 179 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $218.43, for a total transaction of $655,290.00. Following the sale, the insider directly owned 137,643 shares in the company, valued at approximately $30,065,360.49. The trade was a 2.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the sale, the director owned 1,076,198 shares in the company, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 156,530 shares of company stock worth $33,914,062 in the last 90 days. 5.05% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on NTRA. Evercore restated an “outperform” rating and issued a $270.00 price target on shares of Natera in a research report on Friday, May 8th. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Morgan Stanley decreased their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. BTIG Research decreased their price target on shares of Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Finally, Robert W. Baird set a $265.00 price target on shares of Natera in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.12.

Natera Stock Performance

Shares of Natera stock opened at $215.31 on Friday. The firm’s 50-day simple moving average is $204.19 and its 200-day simple moving average is $216.06. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The firm has a market cap of $30.83 billion, a P/E ratio of -132.09 and a beta of 1.56.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.